

WuXi XDC (2268 HK)

Strong earnings growth with strategic acquisition to enhance capacity

WuXi XDC issued a positive profit alert on its 2025 financial performance, expecting revenue to increase by at least 45% YoY and net profit to grow by more than 38% YoY. Notably, the Company expected adjusted net profit before interest income and expenses to rise by more than 45% YoY and by over 65% YoY in 2025 if excluding the impact of foreign exchange fluctuations. In 2025, WuXi XDC signed a record-high 70 new integrated projects, up by 32% YoY. PPQ projects surged by 125% YoY to reach 18, indicating strong potential for commercial manufacturing. To address growing client demand, WuXi XDC announced a cash offer to acquire at least 60% interests in BioDlink (东曜药业, 1875 HK, NR), marking a critical step in further strengthening its manufacturing capacity.

- Global demand for XDC drug R&D and manufacturing continues to grow rapidly.** In 2025, WuXi XDC signed a record-high 70 new integrated projects, up 32% YoY. Among these 70 projects, clients from China and the US were the primary sources. Additionally, 22 of these projects were transferred from external parties, highlighting WuXi XDC's increasing client trust in the global XDC CDMO industry. Furthermore, novel modalities XDC drugs contributed significantly among the 70 newly signed projects, with bispecific ADCs accounted for ~20%, dual-payload ADCs for ~5%, and other types of XDCs for ~17%, demonstrating WuXi XDC's active collaboration with clients in cutting-edge areas of conjugated drug R&Ds. Moreover, PPQ-stage contracts in 2025 increased by 125% YoY to 18, signaling strong growth potential in commercial-stage business. Based on the strong "D-end" enabling capabilities and encouraging commercial business trends, mgmt. of WuXi XDC expects that, by 2030, 20% of the Company's revenue will come from novel XDC projects and another 20% from commercial-stage projects.
- Acquisition of BioDlink set to strengthen production capacity.** WuXi XDC plans to acquire at least 60% interests in BioDlink through a cash tender offer at HK\$4.00 per share, representing a 99% premium over the last closing price of BioDlink on 24 Dec 2025. BioDlink is a leading domestic ADC CDMO service provider with CDMO-related revenue of RMB207mn in 2024. Beyond expanding WuXi XDC's client base, the acquisition will rapidly enhance the Company's drug production capacity to meet strong demand in the moment, particularly for ADC DS and DP, which are currently in short supply. BioDlink operates two mAb facilities with capacities of 500–2,000L/batch, three DS facilities capable of producing over 800kg ADC DS annually, and three DP facilities with an annual capacity exceeding 8mn vials (for comparison, WuXi XDC's DP3 facility has an annual capacity of 8 mn vials).
- Maintain BUY.** We raise our target price to HK\$88.0 to reflect the enhanced global competitiveness and positive demand outlook for WuXi XDC. We forecast WuXi XDC's revenue to grow by 45.7% / 36.6% / 31.7% YoY and adjusted net income to increase by 34.9% / 38.4% / 32.9% YoY in 2025E / 26E / 27E, respectively. As the tender offer for BioDlink is still ongoing, we have not yet incorporated any financial impacts from consolidating BioDlink.

Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (RMB mn)	2,124	4,052	5,906	8,065	10,619
YoY growth (%)	114.4	90.8	45.7	36.6	31.7
Adjusted net profit (RMB m)	412	1,174	1,584	2,192	2,914
YoY growth (%)	112.1	184.8	34.9	38.4	32.9
EPS (Adjusted) (RMB)	0.38	0.91	1.17	1.62	2.15
Consensus EPS (RMB)	na	na	1.30	1.77	2.34
P/E (Adjusted) (x)	171.6	72.0	56.2	40.6	30.5

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$88.00
(Previous TP	HK\$74.00)
Up/Downside	20.7%
Current Price	HK\$72.90

China Healthcare

Benchen HUANG, CFA
 huangbenchen@cmbi.com.hk

Jill WU, CFA
 (852) 3900 0842
 jillwu@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	87,366.6
Avg 3 mths t/o (HK\$ mn)	302.6
52w High/Low (HK\$)	85.10/27.90
Total Issued Shares (mn)	1198.4

Source: FactSet

Shareholding Structure

WuXi Biologics	50.7%
WuXi AppTec	18.6%

Source: HKEx

Share Performance

	Absolute	Relative
1-mth	6.0%	0.9%
3-mth	4.7%	0.8%
6-mth	49.5%	36.6%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	5,906	8,065	10,619	5,906	8,014	10,488	0.00%	0.64%	1.25%
Gross profit	2,107	2,998	4,032	2,037	2,803	3,721	3.45%	6.93%	8.35%
Operating profit	1,806	2,359	3,172	1,812	2,257	2,997	-0.30%	4.55%	5.83%
Non-IFRS net profit	1,584	2,192	2,914	1,643	2,176	2,846	-3.61%	0.74%	2.40%
Non-IFRS EPS (RMB)	1.17	1.62	2.15	1.26	1.68	2.19	-7.63%	-3.47%	-1.87%
Gross margin	35.67%	37.17%	37.97%	34.48%	34.98%	35.48%	+1.19ppt	+2.19ppt	+2.49ppt
Operating margin	30.58%	29.25%	29.87%	30.67%	28.16%	28.58%	-0.09ppt	+1.09ppt	+1.29ppt
Net margin	26.82%	27.18%	27.44%	27.82%	27.16%	27.13%	-1.00ppt	+0.03ppt	+0.31ppt

Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	5,906	8,065	10,619	5,992	8,122	10,576	-1.43%	-0.70%	0.41%
Gross profit	2,107	2,998	4,032	2,045	2,818	3,783	3.01%	6.37%	6.59%
Operating profit	1,806	2,359	3,172	1,646	2,356	3,197	9.72%	0.14%	-0.78%
Non-IFRS net profit	1,584	2,192	2,914	1,621	2,221	2,942	-2.29%	-1.29%	-0.95%
Non-IFRS EPS (RMB)	1.17	1.62	2.15	1.30	1.77	2.34	-9.92%	-8.48%	-8.21%
Gross margin	35.67%	37.17%	37.97%	34.13%	34.70%	35.77%	+1.54ppt	+2.47ppt	+2.20ppt
Operating margin	30.58%	29.25%	29.87%	27.47%	29.01%	30.23%	+3.11ppt	+0.25ppt	-0.36ppt
Net margin	26.82%	27.18%	27.44%	27.05%	27.35%	27.82%	-0.23ppt	-0.16ppt	-0.37ppt

Source: Bloomberg, CMBIGM estimates

Figure 3: Risk-adjusted DCF valuation

DCF Valuation (in Rmb mn)	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E
EBIT	1,614	2,459	3,272	4,255	5,468	6,947	8,720	10,816	13,253	16,041
Tax rate	14.01%	15.53%	15.53%	15.53%	15.53%	15.53%	15.53%	15.53%	15.53%	15.53%
EBIT*(1-tax rate)	1,388	2,077	2,764	3,594	4,619	5,868	7,366	9,137	11,195	13,550
+ D&A	172	235	309	387	479	590	719	870	1,045	1,243
- Change in working capital	-27	-219	-222	-278	-344	-424	-517	-625	-750	-893
- Capex	-1,220	-1,700	-1,800	-1,620	-1,458	-1,312	-1,181	-1,063	-957	-861
FCFF	313	394	1,051	2,083	3,296	4,722	6,388	8,319	10,533	13,039
Terminal value										173,491
Terminal growth rate	2.00%									
WACC	9.67%									
Cost of Equity	13.04%									
Cost of Debt	4.00%									
Equity Beta	1.10									
Risk Free Rate	2.00%									
Market Risk Premium	10.00%									
Target Debt to Asset ratio	35.00%									
Effective Corporate Tax Rate	15.00%									
 PV of terminal value (HK\$bn)	68,953									
Total PV (HK\$bn)	93,694									
Net debt (HK\$bn)	-5,723									
Equity value (HK\$bn)	99,417									
# of shares (mn)	1,255									
Price per share (RMB)	79.20									
Price per share (HK\$)	88.00									

Source: CMBIGM estimates

Figure 4: Sensitivity analysis of DCF model

	WACC					
	8.67%	9.17%	9.67%	10.17%	10.67%	
Terminal growth rate	3.00%	119.91	107.94	97.85	89.24	81.83
	2.50%	112.09	101.56	92.58	84.85	78.12
	2.00%	105.44	96.07	88.00	80.99	74.85
	1.50%	99.72	91.30	83.98	77.58	71.93
	1.00%	94.75	87.11	80.43	74.54	69.31

Source: CMBIGM estimates

Financial Summary

INCOME STATEMENT	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Revenue	990	2,124	4,052	5,906	8,065	10,619
Cost of goods sold	(729)	(1,564)	(2,812)	(3,800)	(5,067)	(6,587)
Gross profit	261	560	1,240	2,107	2,998	4,032
Operating expenses	(66)	(124)	(90)	(301)	(638)	(860)
Selling expense	(9)	(15)	(56)	(129)	(168)	(211)
Admin expense	(49)	(124)	(164)	(262)	(317)	(407)
R&D expense	(34)	(77)	(100)	(130)	(181)	(270)
Others	26	92	230	220	28	28
Operating profit	195	436	1,149	1,806	2,359	3,172
Net Interest income/(expense)	(3)	(1)	(3)	(15)	(3)	3
Others	3	(75)	74	(32)	100	100
Pre-tax profit	196	360	1,220	1,759	2,456	3,275
Income tax	(40)	(76)	(150)	(273)	(381)	(508)
After tax profit	156	284	1,070	1,486	2,075	2,766
Net profit	156	284	1,070	1,486	2,075	2,766
Adjusted net profit	194	412	1,174	1,584	2,192	2,914
BALANCE SHEET	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Current assets	1,402	5,200	6,101	9,869	11,270	13,472
Cash & equivalents	335	4,048	3,540	6,820	7,478	8,829
Account receivables	506	956	1,800	1,961	2,611	3,350
Inventories	63	47	119	112	149	194
Financial assets at FVTPL	400	0	434	734	734	734
Other current assets	99	149	209	244	299	365
Non-current assets	1,094	1,535	3,023	4,071	5,536	7,027
PP&E	799	1,246	2,725	3,782	5,256	6,756
Intangibles	51	53	45	37	28	20
Goodwill	215	215	215	215	215	215
Other non-current assets	30	21	38	37	37	36
Total assets	2,496	6,735	9,124	13,940	16,806	20,498
Current liabilities	1,014	1,279	2,466	3,228	3,901	4,679
Short-term borrowings	71	0	478	1,078	1,228	1,378
Account payables	773	915	1,409	1,570	2,094	2,722
Tax payable	12	34	72	72	72	72
Other current liabilities	7	1	3	3	3	3
Contract liabilities	151	328	504	504	504	504
Non-current liabilities	2	2	18	18	18	18
Obligations under finance leases	2	2	15	15	15	15
Deferred income	0	0	3	3	3	3
Other non-current liabilities	0	0	0	0	0	0
Total liabilities	1,016	1,281	2,485	3,246	3,920	4,698
Share capital	0	0	0	0	0	0
Capital surplus	1,480	5,454	6,639	10,694	12,886	15,800
Total shareholders equity	1,481	5,454	6,639	10,694	12,887	15,801
Total equity and liabilities	2,496	6,735	9,124	13,940	16,806	20,498

CASH FLOW	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	196	360	1,220	1,759	2,456	3,275
Depreciation & amortization	31	60	110	172	235	309
Tax paid	(43)	(48)	(115)	(273)	(381)	(508)
Change in working capital	(6)	(94)	(401)	(27)	(219)	(222)
Others	74	56	(97)	(47)	121	145
Net cash from operations	252	333	717	1,584	2,212	2,998
Investing						
Capital expenditure	(201)	(529)	(1,505)	(1,220)	(1,700)	(1,800)
Others	(1,078)	438	(1,825)	(1,440)	0	0
Net cash from investing	(1,280)	(91)	(3,330)	(2,660)	(1,700)	(1,800)
Financing						
Net borrowings	0	0	478	600	150	150
Proceeds from share issues	0	3,604	0	0	0	0
Others	1,328	(82)	(3)	2,455	(3)	3
Net cash from financing	1,328	3,522	475	3,055	147	153
Net change in cash						
Cash at the beginning of the year	26	335	4,048	1,925	3,905	4,564
Exchange difference	8	(51)	15	0	0	0
Cash at the end of the year	335	4,048	1,925	3,905	4,564	5,915
GROWTH	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Revenue	218.3%	114.4%	90.8%	45.7%	36.6%	31.7%
Gross profit	130.0%	114.3%	121.6%	69.9%	42.3%	34.5%
Operating profit	148.1%	123.0%	163.8%	57.1%	30.6%	34.4%
Net profit	183.5%	82.1%	277.2%	38.9%	39.6%	33.3%
Adj. net profit	152.1%	112.1%	184.8%	34.9%	38.4%	32.9%
PROFITABILITY	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Gross profit margin	26.4%	26.3%	30.6%	35.7%	37.2%	38.0%
Operating margin	19.7%	20.5%	28.4%	30.6%	29.3%	29.9%
Adj. net profit margin	19.6%	19.4%	29.0%	26.8%	27.2%	27.4%
Return on equity (ROE)	20.7%	8.2%	17.7%	17.1%	17.6%	19.3%
GEARING/LIQUIDITY/ACTIVITIES	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
Net debt to equity (x)	(0.2)	(0.7)	(0.5)	(0.5)	(0.5)	(0.5)
Current ratio (x)	1.4	4.1	2.5	3.1	2.9	2.9
Receivable turnover days	120.8	125.6	124.2	121.2	118.2	115.2
Inventory turnover days	21.7	12.8	10.7	10.7	10.7	10.7
Payable turnover days	398.4	197.0	150.8	150.8	150.8	150.8
VALUATION	2022A	2023A	2024A	2025E	2026E	2027E
YE 31 Dec						
P/E (diluted)	na	171.6	72.0	56.2	40.6	30.5
P/B	na	12.2	11.8	7.7	6.4	5.2
P/CFPS	na	200.4	108.9	51.7	37.0	27.3

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY	: Stock with potential return of over 15% over next 12 months
HOLD	: Stock with potential return of +15% to -10% over next 12 months
SELL	: Stock with potential loss of over 10% over next 12 months
NOT RATED	: Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.